- Home
- VNT vs TVTX Comparison
VNT vs TVTX Comparison
Compare VNT & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNT | TVTX |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.7B |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | VNT | TVTX |
|---|---|---|
| Price | $43.48 | $51.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $45.25 | ★ $73.43 |
| AVG Volume (30 Days) | 1.5M | ★ 2.2M |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | 0.36 | ★ 92.89 |
| EPS | ★ 1.58 | N/A |
| Revenue | ★ $3,075,600,000.00 | N/A |
| Revenue This Year | N/A | $55.96 |
| Revenue Next Year | $0.78 | $48.63 |
| P/E Ratio | $27.26 | ★ N/A |
| Revenue Growth | ★ 3.24 | N/A |
| 52 Week Low | $27.25 | $22.59 |
| 52 Week High | $48.20 | $68.73 |
Technical Indicators
Market Signals| Indicator | VNT | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 84.12 | 46.64 |
| Support Level | $34.43 | $49.46 |
| Resistance Level | $48.20 | $54.43 |
| Average True Range (ATR) | 1.42 | 2.65 |
| MACD | 0.85 | 0.52 |
| Stochastic Oscillator | 92.62 | 78.53 |
Price Performance
Historical ComparisonAbout VNT Vontier Corporation
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3.1 billion in sales in 2025.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.